study,trt,class,n,r
ang 2013,cognitive behavioural therapy ,nonad,19,4
ang 2013,cognitive behavioral therapy and milnacipran ,snri,20,8
ang 2013,milnacipran ,snri,18,7
arnold 2005,placebo,placebo,118,39
arnold 2005,duloxetine ,snri,116,64
arnold 2005,duloxetine ,snri,113,61
arnold 2010: 1,placebo,placebo,133,30
arnold 2010: 1,esreboxetine ,snri,133,50
arnold 2010: 2,placebo,placebo,509,156
arnold 2010: 2,milnacipran ,snri,516,230
arnold 2010: 3,placebo,placebo,248,66
arnold 2010: 3,duloxetine ,snri,249,90
arnold 2012: 1,placebo,placebo,153,66
arnold 2012: 1,duloxetine ,snri,153,76
arnold 2012: 2,placebo,placebo,276,77
arnold 2012: 2,esreboxetine ,snri,273,101
arnold 2012: 2,esreboxetine ,snri,279,110
arnold 2012: 2,esreboxetine ,snri,280,95
bateman 2011,milnacipran ,snri,79,27
bateman 2011,placebo,placebo,21,6
chappell 2008,placebo,placebo,167,55
chappell 2008,duloxetine ,snri,158,60
chappell 2009: 2,placebo,placebo,120,53
chappell 2009: 2,duloxetine ,snri,111,64
chappell 2011,placebo,placebo,128,58
chappell 2011,duloxetine ,snri,128,79
clauw 2008,placebo,placebo,401,115
clauw 2008,milnacipran ,snri,399,149
clauw 2008,milnacipran ,snri,396,158
enomoto 2018,pregabalin ,nonad,151,94
enomoto 2018,duloxetine ,snri,152,100
frakes 2011,placebo,placebo,260,76
frakes 2011,duloxetine ,snri,264,111
gao 2010,placebo,placebo,109,67
gao 2010,duloxetine ,snri,106,74
gao 2015,placebo,placebo,198,97
gao 2015,duloxetine ,snri,200,123
gillving 2021,terbutaline ,nonad,39,6
gillving 2021,imipramine ,tca,44,16
gillving 2021,placebo,placebo,38,5
gould 2020,placebo,placebo,33,13
gould 2020,desipramine ,tca,37,18
gould 2020,cognitive behavioural therapy ,nonad,34,12
gould 2020,desipramine + cognitive behavioural therapy ,tca,37,15
holbech 2015,placebo,placebo,69,10
holbech 2015,pregabalin ,nonad,69,16
holbech 2015,imipramine ,tca,69,20
holbech 2015,pregabalin + imipramine ,tca,69,36
kaur 2011,amitriptyline ,tca,58,36
kaur 2011,duloxetine ,snri,58,37
mease 2009,placebo,placebo,145,58
mease 2009,milnacipran ,snri,128,68
mease 2009,milnacipran ,snri,239,134
miki 2016,placebo,placebo,211,65
miki 2016,mirtazapine ,nassa,211,96
pickering 2018,placebo,placebo,24,6
pickering 2018,milnacipran ,snri,24,7
raskin 2005,placebo,placebo,113,49
raskin 2005,duloxetine ,snri,113,77
raskin 2005,duloxetine ,snri,114,73
razazian 2014,carbamazepine ,nonad,85,39
razazian 2014,pregabalin ,nonad,86,14
razazian 2014,venlafaxine ,snri,86,20
rintala 2007,gabapentin ,nonad,22,7
rintala 2007,amitriptyline ,tca,22,12
rintala 2007,placebo,placebo,22,7
russell 2008,placebo,placebo,144,54
russell 2008,duloxetine ,snri,79,41
russell 2008,duloxetine ,snri,150,71
russell 2008,duloxetine ,snri,147,43
shinichi 2016,placebo,placebo,226,118
shinichi 2016,duloxetine ,snri,232,159
skljarevski 2009,placebo,placebo,113,49
skljarevski 2009,duloxetine ,snri,56,23
skljarevski 2009,duloxetine ,snri,110,59
skljarevski 2009,duloxetine ,snri,109,63
skljarevski 2010: 1,placebo,placebo,115,45
skljarevski 2010: 1,duloxetine ,snri,109,51
skljarevski 2010: 2,placebo,placebo,199,97
skljarevski 2010: 2,duloxetine ,snri,195,111
smith 2013,placebo,placebo,94,16
smith 2013,duloxetine ,snri,87,29
tesfaye 2013,pregabalin ,nonad,374,138
tesfaye 2013,duloxetine ,snri,375,195
uchio 2018,placebo,placebo,176,88
uchio 2018,duloxetine ,snri,177,124
vitton 2004,placebo,placebo,28,6
vitton 2004,milnacipran ,snri,46,16
vitton 2004,milnacipran ,snri,51,20
vollmer 2014,placebo,placebo,120,29
vollmer 2014,duloxetine ,snri,115,44
wang 2017,placebo,placebo,197,98
wang 2017,duloxetine ,snri,194,123
wernicke 2006,placebo,placebo,106,45
wernicke 2006,duloxetine ,snri,110,69
wernicke 2006,duloxetine ,snri,111,77
yasuda 2011,placebo,placebo,167,59
yasuda 2011,duloxetine ,snri,85,47
yasuda 2011,duloxetine ,snri,86,51
yeephu 2013,placebo,placebo,13,5
yeephu 2013,mirtazapine ,nassa,13,7
yeephu 2013,mirtazapine ,nassa,14,9